Form 8-K - Current report:
SEC Accession No. 0001683168-24-005713
Filing Date
2024-08-14
Accepted
2024-08-14 17:25:50
Documents
14
Period of Report
2024-08-09
Items
Item 4.02: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT coeptis_8k.htm   iXBRL 8-K 38492
  Complete submission text file 0001683168-24-005713.txt   261883

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE coep-20240809.xsd EX-101.SCH 3873
3 XBRL DEFINITION FILE coep-20240809_def.xml EX-101.DEF 26773
4 XBRL LABEL FILE coep-20240809_lab.xml EX-101.LAB 37006
5 XBRL PRESENTATION FILE coep-20240809_pre.xml EX-101.PRE 25397
16 EXTRACTED XBRL INSTANCE DOCUMENT coeptis_8k_htm.xml XML 6127
Mailing Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090
Business Address 105 BRADFORD ROAD, SUITE 420 WEXFORD PA 15090 724-934-6467
Coeptis Therapeutics Holdings, Inc. (Filer) CIK: 0001759186 (see all company filings)

EIN.: 981465952 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39669 | Film No.: 241209670
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)